Pfizer’s Hospira Draws Warning Letter for Quality Defects

Drug GMP Report
A A
The FDA hit Pfizer’s Hospira for failing to fully investigate quality defects, such as the presence of cardboard, in batches of injections and neglecting to take corrective measures.

To View This Article:

Login

Subscribe To Drug GMP Report